东亚药业
(605177)
| 流通市值：21.65亿 | | | 总市值：22.06亿 |
| 流通股本：1.13亿 | | | 总股本：1.15亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 415,858,305.39 | 190,921,213.83 | 1,198,238,535.39 | 963,019,242.47 |
| 营业收入 | 415,858,305.39 | 190,921,213.83 | 1,198,238,535.39 | 963,019,242.47 |
| 二、营业总成本 | 425,107,404.13 | 193,939,111.07 | 1,173,707,357.93 | 914,079,555.24 |
| 营业成本 | 290,462,901.6 | 123,394,635.74 | 865,663,163.87 | 703,230,309.84 |
| 税金及附加 | 5,138,105.93 | 2,437,450.15 | 11,362,718.63 | 8,539,592.24 |
| 销售费用 | 7,077,804.56 | 1,759,543.49 | 15,387,268.47 | 10,982,915.66 |
| 管理费用 | 78,081,656.88 | 43,208,414.35 | 170,269,093.67 | 127,438,407.37 |
| 研发费用 | 42,365,947.12 | 23,009,005.87 | 117,016,684.56 | 67,140,483.98 |
| 财务费用 | 1,980,988.04 | 130,061.47 | -5,991,571.27 | -3,252,153.85 |
| 其中:利息费用 | 5,095,918.51 | 1,936,606.19 | 2,039,662.8 | 2,478,028.51 |
| 其中:利息收入 | 2,516,608.4 | 1,306,491.43 | 5,674,745.08 | 4,289,818.64 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 1,467,591.82 | 737,521.13 | 3,943,815.78 | 3,342,771.63 |
| 资产处置收益 | -4,303.49 | -5,963.93 | -3,130,864 | -90,624.45 |
| 资产减值损失(新) | -31,980,426.01 | -12,629,703.08 | -144,052,482.6 | -3,552,573.56 |
| 信用减值损失(新) | -43,149.17 | 3,330,066.74 | -1,179,208.39 | -3,315,686.94 |
| 其他收益 | 7,288,309.1 | 3,955,914.04 | 18,154,530.35 | 14,544,601.08 |
| 四、营业利润 | -32,521,076.49 | -7,630,062.34 | -101,733,031.4 | 59,868,174.99 |
| 加:营业外收入 | 187,455.29 | 76,004.56 | 526,138.61 | 30,148 |
| 减:营业外支出 | 1,811,629.06 | 84,964.95 | 16,965,194.78 | 4,445,608.27 |
| 五、利润总额 | -34,145,250.26 | -7,639,022.73 | -118,172,087.57 | 55,452,714.72 |
| 减:所得税费用 | -3,880,698.64 | -694,118.56 | -17,472,628.07 | 10,296,716.32 |
| 六、净利润 | -30,264,551.62 | -6,944,904.17 | -100,699,459.5 | 45,155,998.4 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -30,264,551.62 | -6,944,904.17 | -100,699,459.5 | 45,155,998.4 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -30,228,272.8 | -6,919,576.54 | -100,660,051.84 | 45,169,152.65 |
| 少数股东损益 | -36,278.82 | -25,327.63 | -39,407.66 | -13,154.25 |
| 扣除非经常损益后的净利润 | -35,880,868.77 | -10,505,893.27 | -98,408,150.01 | 38,084,911.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.26 | -0.06 | -0.9 | 0.4 |
| (二)稀释每股收益 | -0.2 | -0.05 | -0.69 | 0.31 |
| 九、综合收益总额 | -30,264,551.62 | -6,944,904.17 | -100,699,459.5 | 45,155,998.4 |
| 归属于母公司股东的综合收益总额 | -30,228,272.8 | -6,919,576.54 | -100,660,051.84 | 45,169,152.65 |
| 归属于少数股东的综合收益总额 | -36,278.82 | -25,327.63 | -39,407.66 | -13,154.25 |
| 公告日期 | 2025-08-29 | 2025-04-30 | 2025-04-30 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |